MAIA Biotechnology (MAIA) Expected to Release Quarterly Earnings on Friday

MAIA Biotechnology (NYSEAMERICAN:MAIA – Get Free Report) is expected to be issuing its Q3 2026 resultson Friday, November 6th. Analysts expect MAIA Biotechnology to post earnings of ($0.13) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 6, 2026 at 9:30 AM ET.

MAIA Biotechnology (NYSEAMERICAN:MAIA – Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, analysts expect MAIA Biotechnology to post ($0.54) EPS for the current fiscal year and ($0.48) EPS for the next fiscal year.

MAIA Biotechnology Price Performance

Shares of MAIA stock opened at $1.18 on Friday. The company has a market capitalization of $72.85 million, a P/E ratio of -1.90 and a beta of 0.27. The company’s 50-day simple moving average is $1.25 and its two-hundred day simple moving average is $1.46. MAIA Biotechnology has a one year low of $0.87 and a one year high of $3.19.

Insider Activity at MAIA Biotechnology

In other news, CEO Vlad Vitoc acquired 73,000 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The shares were bought at an average price of $1.37 per share, with a total value of $100,010.00. Following the completion of the purchase, the chief executive officer directly owned 1,049,121 shares in the company, valued at $1,437,295.77. This trade represents a 7.48% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ramiro Guerrero acquired 37,595 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The stock was purchased at an average cost of $1.32 per share, for a total transaction of $49,625.40. Following the purchase, the director owned 773,296 shares of the company’s stock, valued at $1,020,750.72. This represents a 5.11% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 258,078 shares of company stock valued at $352,426 in the last ninety days. Insiders own 19.81% of the company’s stock.

About MAIA Biotechnology

(Get Free Report)

MAIA Biotechnology, Inc is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company’s research is centered on treatments designed to address telomere biology, a process that plays an important role in the growth and survival of cancer cells.

MAIA’s lead investigational product is THIO, also known as 6-thio-2′-deoxyguanosine, a telomere-targeting agent intended to selectively affect cancer cells. The company has been evaluating THIO in combination with immune checkpoint inhibitors for patients with advanced or metastatic non-small cell lung cancer, including through its THIO-101 clinical program.

MAIA Biotechnology is headquartered in Chicago and is led by Chief Executive Officer Vlad Vitoc, M.D.

See Also

Earnings History for MAIA Biotechnology (NYSEAMERICAN:MAIA)

Receive News & Ratings for MAIA Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAIA Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.